Harrow’s latest earnings and guidance in focus
Harrow (HROW) is back in the spotlight after reporting record third quarter revenue of US$99.3 million, returning to profitability and reaffirming its full year revenue guidance while introducing its new HarrowRx pharmacy platform.
The recent quarterly update and HarrowRx launch arrived after a volatile stretch for Harrow’s stock, with a 7 day share price return of 12.79% but a year to date share price decline of 41.15%. The 3 year total shareholder return of about 2.4x still reflects a very strong longer term outcome.
Compare Harrow’s earnings rebound and HarrowRx launch with a curated group of companies showing similar potential by reviewing the 19 high quality undiscovered gems.
For Harrow, a 7 day rebound and a sharply lower year to date share price tell two very different stories. Is this latest move about the earnings and HarrowRx launch, or is it simply a swing in sentiment that the valuation now needs to sort out?
Most Popular Narrative: 53% Undervalued
On the analyst consensus Narrative on Simply Wall St, Harrow’s fair value of $63 sits well above the last close at $29.37. This frames the recent rebound as small compared to the gap implied by that work.
Harrow is expanding from its compounding roots into a broader branded ophthalmic portfolio with products such as VEVYE, IHEEZO, TRIESENCE, BYOOVIZ, VERKAZIA, BYQLOVI, IOPIDINE and TYRVAYA. This supports a shift toward a multi-franchise model that can add more diversified revenue streams and scale benefits for earnings.
The buildout of Harrow’s commercial infrastructure, including the doubling of the VEVYE sales force, tripling of the surgical commercial team and the expected integration of experienced TYRVAYA representatives, gives the company more reach across dry eye and surgical channels. This can help translate existing product breadth into higher revenue and better utilization of fixed SG&A.
See why 15 investors see Harrow as 53% undervalued.
Result: Fair Value of $63 (UNDERVALUED)
Still, Harrow’s dependence on a handful of flagship drugs, along with the need to hit ambitious 2026 revenue and adjusted EBITDA goals, could easily test that bullish narrative.
Find out about the key risks to this Harrow narrative.
Next Steps
Curious whether the optimism in this Harrow story fits your own risk and reward tradeoff? Review the data for yourself and pressure test every assumption by checking the 3 key rewards.
Looking for more Harrow-sized investment ideas?
Do not stop your research with Harrow. Broaden your watchlist using fresh ideas from the Simply Wall St Screener and avoid leaving potential opportunities on the table.
- Target resilient income by reviewing stocks in the 6 dividend fortresses that combine higher yields with a focus on durability.
- Hunt for mispriced quality through the 32 high quality undervalued stocks that highlights companies with solid fundamentals trading below their assessed worth.
- Prioritise capital protection by assessing candidates in the 30 resilient stocks with low risk scores that score well on financial strength and volatility controls.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com